Used as an auxiliary in difficulties with expectoration occurring in inflammation and infections of the upper respiratory tract.
Expectorant lozenges (GlaxoSmithKline Pharmaceuticals SA – Polska)
| form, dose, packaging | availability category | the active substance |
| hard lozenges (16 lozenges) | OTC (over-the-counter) | licorice root, sulfowaacol (glycyrrhizae radix, sulfoguaiacol) |
SUBSTANCE 1 tablet contains: 0,2 g of sulfogwaacol, 0,01 g of dry extract of licorice root
ACTION
A combined preparation with an expectorant effect
INDICATIONS AND DOSAGE
Supportive in difficulties with expectoration occurring in inflammation and infections of the upper respiratory tract. Lozenges should be sucked between meals. Adults. 1-2 tablets 3–4 × / day, max. 8 tablets / day Children 3-16 years old rż. 1 tablet 3 × / day, max. 3 tablets / day Do not use for more than 4-6 days.
CONTRAINDICATIONS
Hypersensitivity to any component of the preparation, liver inflammation with cholestasis, cirrhosis, acute renal failure, hypertension, hypokalemia, diabetes, pregnancy, breastfeeding. Do not use in children <3. rż. In children 3–6. years. use with caution due to the possibility of choking.
WARNINGS
Patients with hereditary disorders of fructose intolerance, malabsorption of glucose-galactose or sucrase-isomaltase deficiency should not use the preparation (the preparation contains sucrose). There are no studies on the effect of the preparation on the ability to drive motor vehicles.
INTERACTIONS
So far not stated; possible increased loss of potassium from the body in the case of high doses. Therefore, caution should be exercised when using cardiac glycosides with diuretics that may increase potassium loss. Too high doses of the preparation may also intensify the effect of the corticosteroids used.
SIDE EFFECTS
The following may occur: nausea, vomiting, anorexia, burning tongue, diarrhea. These symptoms resolve spontaneously after treatment is discontinued.